Research programme: age-related macular degeneration therapeutics - Dong-A ST

Drug Profile

Research programme: age-related macular degeneration therapeutics - Dong-A ST

Alternative Names: DA-3131

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator Dong-A ST
  • Class Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 09 Oct 2015 Research programme: age-related macular degeneration therapeutics - Dong-A ST is available for licensing -http://en.donga-st.com/Pass.da?viewPath=/b02/licenseOut
  • 03 Sep 2015 Preclinical trials in Age-related macular degeneration in South Korea (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top